Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma.
In order to assess the efficacy and toxicity profile of oxaliplatin, a third generation platinum derivate active against several solid tumors, we carried out a study in a group of heavily pretreated patients with non-Hodgkin's lymphoma (NHL). Between August 2003 and May 2004, 19 pretreated patients were enrolled in a phase II trial and were treated with oxaliplatin. The drug was administered intravenously on day 1 of a 21-day schedule, at a dose of 130 mg/m2 for a total of 6 cycles. One (5%) patient achieved complete remission (CR) and 5 patients (27%) had partial response (PR), thus giving an overall response rate of 32%. The patient in CR suffered from an aggressive B NHL. One of the 5 patients in PR had an aggressive B NHL, whereas the remaining 4 had an indolent B NHL. The treatment was well tolerated with minimal hematologic and extrahematologic toxicity. These data suggest and confirm the efficacy and low toxicity of oxaliplatin in the treatment of patients with heavily pretreated NHL. Further trials using oxaliplatin alone or in combination with other conventional drugs are needed.
Alinari
Lapo
L
Institute of Hematology and Medical Oncology Seràgnoli, University of Bologna, Bologna, Italy
Musuraca
Gerardo
G
Tani
Monica
M
Stefoni
Vittorio
V
Gabriele
Annalisa
A
Marchi
Enrica
E
Fina
Mariapaola
M
De Vivo
Antonio
A
Pileri
Stefano
S
Baccarani
Michele
M
Zinzani
Pier Luigi
PL
D000368:Aged; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077150:Oxaliplatin
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin